



DAFTAR PUSTAKA

1. Andary MT, Klein MJ. Guillain-Barre Syndrome. 2021;1–23. Available from: 10/31https://emedicine.medscape.com/article/315632-print
2. DiFazio MP, Jallo GI. Pediatric Guillain-Barre Syndrome. Emedicine. 2019;1–15. Available from: <https://emedicine.medscape.com/article/1180594-print>
3. Khairani AF, Karina M, Siswanti LH, Dewi MM. Clinical Profile of Pediatric Guillain-Barré Syndrome : A Study from National Referral Hospital in West Java, Indonesia. Biomed. & Pharmacol. J. 2019;12(December):2043–8.
4. Hutasuhut F. Profil Anak dengan Sindrom Guillain Barre di RSUP H. Adam Malik Medan: Kejadian dalam 5 Tahun. USU. 2021.
5. Ulfa M, Widowati T, Triono A. Erasmus Guillain-Barre Syndrome Outcome Score (EGOS) to predict functional outcomes. Paediatr Indones. 2022;62(2):130–7.
6. Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain – Barré syndrome in low- income and middle- income countries : challenges and prospects. Nat Rev Neurol [Internet]. 2021;0123456789. Available from: <http://dx.doi.org/10.1038/s41582-021-00467-y>
7. Akbayram S, Do M, Akgün C, Peker E, Say R, Aktar F, et al. Clinical features and prognosis with Guillain-Barré syndrome. Ann Indian Acad Neurol. 2011;14(2):98-102.
8. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet [Internet]. 2016;388(10045):717–27. Available from: [http://dx.doi.org/10.1016/S0140-6736\(16\)00339-1](http://dx.doi.org/10.1016/S0140-6736(16)00339-1)
9. M. Hussein L, H. Ali S, H. Mohammed N. Electrophysiological evaluation of Guillain–Barre syndrome subtypes in childhood. J Fac Med. 2017;59(1):60–4.
10. Hughes RA, Cornblath DR. Guillain-Barré Syndrome. Lancet. 2020;26(5):1184–204.
11. Mitsui Y, Kusunoki S, Arimura K, Kaji R, Kanda T, Kuwabara S, et al. A multicentre prospective study of Guillain-Barré Syndrome in Japan: A focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry. 2015;86(1):110–4.
12. Dourado Júnior MET, Fernandes UT, Ramos ES, Vital ALF, Urbano JCC, Queiroz JW, et al. Egos has a reduced capacity to predicts GBS prognosis in Northeast Brazil. Acta Neurol Scand. 2018;138(5):459–62.



13. Wakerley BR, Uncini A, Yuki N. Guillain-Barré and miller fisher syndromes - New diagnostic classification. *Nat Rev Neurol* [Internet]. 2014;10(9):537–44. Available from: <http://dx.doi.org/10.1038/nrneurol.2014.138>
14. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of. *Nat Rev Neurol* [Internet]. 2019; Available from: <http://dx.doi.org/10.1038/s41582-019-0250-9>
15. Kieseier BC, Hartung HP, Wiendl H. Immune circuitry in the peripheral nervous system. *Curr Opin Neurol*. 2006;19(5):437–45.
16. Hadden RDM, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. *Neurology*. 2001;56(6):758–65.
17. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of *Campylobacter jejuni* isolated from patients with Guillain-Barre syndrome and Miller Fisher syndrome. *J Infect Dis*. 1997;176(6 SUPPL.):150–3.
18. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. *Ann Neurol*. 1990;27(1 S):S21–4.
19. Tsurayya Z. Karakteristik Demografis dan Klinis Guillain Barre Syndrome. Fak Kedokteran, Kesehat Masyarakat, dan Keperawatan Universitas Gadjah Mada. UGM. 2020.
20. van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). *Press Medicale* [Internet]. 2013;42(6 PART2):e193–201. Available from: <http://dx.doi.org/10.1016/j.lpm.2013.02.328>
21. Draak THP, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, et al. Does ability to walk reflect general functionality in inflammatory neuropathies? *J Peripher Nerv Syst*. 2016;21(2):74–81.
22. Wang Y, Zhang HL, Wu X, Zhu J. Complications of Guillain-Barré syndrome. *Expert Rev Clin Immunol*. 2016;12(4):439–48.
23. Bernsen RAJAM, De Jager AEJ, Kuijer W, Van Der Meché FGA, Suurmeijer TPBM. Psychosocial dysfunction in the first year after Guillain-Barré syndrome. *Muscle and Nerve*. 2010;41(4):533–9.
24. Epstein SK. Respiratory muscle weakness due to neuromuscular disease: Management. *UpToDate*. 2016;1–14. Available from: <https://www.uptodate.com/contents/respiratory-muscle-weakness-due-to-neuromuscular-disease-management/print?topicRef=5121&source=related%E2%80%A6>
25. Roodbol J, De Wit MCY, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barré syndrome in children. *J Peripher Nerv Syst*.



- 2014;19(2):121–6.
26. Roubenoff RA, Borel CO, Hanley DF. Hypermetabolism and hypercatabolism in Guillain-Barre syndrome. *J Parenter Enter Nutr.* 1992;16(5):464–72.
 27. Zhang B, Wu X, Shen D, Li T, Li C, Mao M, et al. The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome. *Med (United States).* 2017;96(1):1–6.
 28. Doets AY, Jacobs BC, van Doorn PA. Advances in management of Guillain–Barré syndrome. *Curr Opin Neurol.* 2018;31(5):541–50.
 29. McDonnell EP, Altomare NJ, Parekh YH, Gowda RC, Parikh PD, Lazar MH, et al. COVID-19 as a trigger of recurrent Guillain–Barré syndrome. *Pathogens.* 2020;9(11):1–9.
 30. Barzegar M, Toopchizadeh V, Maher MHK, Sadeghi P, Jahanjoo F, Pishgahi A. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. *Pediatr Res [Internet].* 2017;82(2):333–9. Available from: <http://dx.doi.org/10.1038/pr.2017.67>
 31. van Koningsveld R, Steyerberg EW, Hughes RA, Swan A V., van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. *Lancet Neurol.* 2007;6(7):589–94.
 32. Rajabally YA, Uncini A. Outcome and its predictors in Guillaine-Barré syndrome. *J Neurol Neurosurg Psychiatry.* 2012;83(7):711–8.
 33. Okoromah CAN, Ekure EN, Lesi FEA, Okunowo WO, Tijani BO, Okeiyi JC. Prevalence, profile and predictors of malnutrition in children with congenital heart defects: A case-control observational study. *Arch Dis Child.* 2011;96(4):354–60.
 34. De Souza Menezes F, Leite HP, Koch Nogueira PC. Malnutrition as an independent predictor of clinical outcome in critically illchildren. *Nutrition [Internet].* 2012;28(3):267–70. Available from: <http://dx.doi.org/10.1016/j.nut.2011.05.015>
 35. Parr A, Askin G. Paediatric scoliosis Update on assessment and treatment. *Aust J Gen Pract.* 2020;49(12):832–7.
 36. Mo F, Cunningham ME. Pediatric scoliosis. *Curr Rev Musculoskelet Med.* 2011;175–82.
 37. Rüwald JM, Upenieks J, Ositis J, Pycha A, Avidan Y, Rüwald AL, et al. Pediatric Scoliosis Surgery — A Comprehensive Analysis of Treatment-Specific Variables and Trends in Latvia. *Medicina.* 2020;56(201). doi:10.3390/medicina56040201
 38. Cuestas G, Navacchia D, Munz PB, Munz B. Tratamiento quirúrgico de la



- estenosis traqueal adquirida en pediatría. Arch Argent Pediatr. 2020;118(1):72–6.
39. Yadav N, Ahmad SR, Kumar N, Mishra B. Airway Management of a Post Tracheostomy Stenosis Patient With Respiratory Difficulty : Make Sure You Have Fibre Optic Guidance Before Administering a Muscle Relaxant. Trauma Mon. 2016;21(3):4–5.
 40. Weber TR, Connors RH, Tracy TF, Louis S. Acquired tracheal stenosis in infants and children. J Thorac Cardiovasc Surg [Internet]. 1991;102(1):29–35. Available from: [http://dx.doi.org/10.1016/S0022-5223\(19\)36581-X](http://dx.doi.org/10.1016/S0022-5223(19)36581-X)
 41. Schweiger C, Manica D. Ongoing Laryngeal Stenosis : Conservative Management and Alternatives to Tracheostomy. Front. Pediatr. 2020;8(April):1–8.
 42. Kementerian Kesehatan Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 2 Tahun 2020 Tentang Standar Antropometri Anak. 2020;(1):1–78. Available from: <https://doi.org/10.1016/j.solener.2019.02.027> <https://www.golder.com/insights/block-caving-a-viable-alternative/>
 43. World Health Organization. Malnutrition. WHO. 2021;(June):1–5.
 44. Rah JH, Melse-Boonstra A, Agustina R, van Zutphen KG, Kraemer K. The Triple Burden of Malnutrition Among Adolescents in Indonesia. Food Nutr Bull. 2021;42(1_suppl):S4–8.
 45. McLachlan M. Adolescent nutrition At A Glance. Semin Adolesc Med. 2003;1(1):55–65.
 46. Elder EIR and LK. Nutrition of Women and Adolescent Girls: Why It Matters. Popul Ref Bur [Internet]. 2003;1–16. Available from: <http://www.prb.org/Publications/Articles/2003/NutritionofWomenandAdolescentGirlsWhyItMatters.aspx>
 47. Christian P, Smith ER. Adolescent Undernutrition: Global Burden, Physiology, and Nutritional Risks. Ann Nutr Metab. 2018;72(4):316–28.
 48. Imam K, Liu A. A case of Recurrent Guillain-Barre Syndrome observed by the same clinician 12 years apart. Clin Case Reports. 2020;8(8):1376–8.
 49. Das A, Kalita J, Misra UK. Recurrent Guillain Barre' syndrome. Electromyogr Clin Neurophysiol. 2004;44(2):95-102. PMID: 15061403.
 50. Torok DP. Physical Therapy Rehabilitation In A Patient With Guillain-Barre Syndrome With Acute Respiratory Failure : A Case Report. Physical Therapy Scholarly Projects. 2020;1–48.
 51. Fafolahan AO, Olatunji TO, Davis AO, Sodipo OP, Adeoye KK, Musa BO, et al.



Pediatric rehabilitation post Guillain-Barré syndrome: a case report at Federal Medical Centre, Abeokuta. *Int J Contemp Pediatr.* 2022;9(10):955.

52. Weinstein SL, Dolan LA, Wright JG, Dobbs, MB. Effects of bracing in adolescents with idiopathic scoliosis. *N Engl J Med.* 2013; 369(16): 1512–1521. doi:10.1056/NEJMoa1307337.
53. Weiss HR, Colak TK, Lay M, Borysov M. Brace treatment for patients with scoliosis: state of the art. *S. Afr. J. Physiother.* 2021; 77(2), a1573. <https://doi.org/10.4102/sajp.v77i2.1573>.
54. Kaelin AJ. Adolescent idiopathic scoliosis: indications for bracing and conservative treatment. *Ann Transl Med.* 2020;8(2):28. <http://dx.doi.org/10.21037/atm.20>.
55. Ikatan Dokter Anak Indonesia. Jadwal imunisasi anak umur 0-18 tahun. 2023. Available from: <https://www.idai.or.id/artikel/klinik/imunisasi/jadwal-imunisasi-anak-idai>.
56. Center for Disease Control and Prevention. Pneumococcal Vaccination. 2022. Available from: <https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html>
57. Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. *Euro Surveill.* 2023;28(21):pii=2300116. <https://doi.org/10.2807/1560-7917.ES.2023.28.21.2300116>.